Moderna, Inc. (MRNA) 今日盘前股价大幅上涨5.06%，引起了市场的广泛关注。
消息面上，多重积极因素共同推动了此次股价上扬。首先，Moderna宣布已达成协议，将支付最高22.5亿美元，以了结与其新冠疫苗相关的专利纠纷。这一重大和解协议消除了笼罩在该公司头顶的一大不确定性，为市场注入了积极情绪。与此同时，Roivant Sciences Ltd.旗下子公司Genevant Sciences将向Moderna授予一项用于传染病领域的脂质纳米颗粒（LNP）递送技术的非独占许可，此举解决了双方长期存在的知识产权争议，为公司核心mRNA技术的应用扫清了潜在障碍。
此外，公司发布了最新的财务展望，预计将在2026年恢复营收增长，并在该财年末保持超过50亿美元的流动性储备，目标是在2028年实现盈亏平衡。这一系列积极的财务预测显著增强了投资者对公司后疫情时代可持续发展能力的信心。市场分析也指出，公司积极拥抱“AI+医疗”浪潮的战略布局，为未来发展提供了新的想象空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.